CLOs on the Move

Incyte

www.incyte.com

 
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.incyte.com
  • 1801 Augustine Cut-off
    Wilmington, DE USA 19880
  • Phone: 855.446.2983

Executives

Name Title Contact Details
Pamela Politis
 Associate Vice President, North American Legal Profile
Sarah diFrancesca
 Executive Director of Compliance, Dermatolgy Lead Profile
Scott Larsen
 Vice President, IP Profile
Stephen Ferenchick
 Executive Director, Corporate Counsel Profile
Paul Quinones
 Vice President, Corporate Counsel, Development Profile

Similar Companies

Meta Systems

Meta Systems is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tibotec

Tibotec (tee-bo-tek) Therapeutics was established in March 2003 as a division of Ortho Biotech Products, L.P. Headquartered in Bridgewater, N.J., the organization is dedicated to providing innovative virology therapeutics that help healthcare

Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases.

Frequency Therapeutics

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.